Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Brunner AM, Esteve J, Porkka K, Knapper S, Traer E, Scholl S, Garcia-Manero G, Vey N, Wermke M, Janssen JJWM, Narayan R, Fleming S, Loo S, Tovar N, Kontro M, Ottmann OG, Naidu P, Sun H, Han M, White R, Zhang N, Mohammed A, Sabatos-Peyton CA, Steensma DP, Rinne ML, Borate UM, Wei AH. Brunner AM, et al. Among authors: ottmann og. Am J Hematol. 2024 Feb;99(2):E32-E36. doi: 10.1002/ajh.27161. Epub 2023 Nov 22. Am J Hematol. 2024. PMID: 37994196 Clinical Trial.
Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
Chiriches C, Khan D, Wieske M, Guillen N, Rokicki M, Guy C, Wilson M, Heesom KJ, Ottmann OG, Ruthardt M. Chiriches C, et al. Among authors: ottmann og. Ann Hematol. 2022 Oct;101(10):2179-2193. doi: 10.1007/s00277-022-04905-9. Epub 2022 Aug 8. Ann Hematol. 2022. PMID: 35941390 Free PMC article.
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial.
Döhner H, Symeonidis A, Deeren D, Demeter J, Sanz MA, Anagnostopoulos A, Esteve J, Fiedler W, Porkka K, Kim HJ, Lee JH, Usuki K, D'Ardia S, Won Jung C, Salamero O, Horst HA, Recher C, Rousselot P, Sandhu I, Theunissen K, Thol F, Döhner K, Teleanu V, DeAngelo DJ, Naoe T, Sekeres MA, Belsack V, Ge M, Taube T, Ottmann OG. Döhner H, et al. Among authors: ottmann og. Hemasphere. 2021 Aug 2;5(8):e617. doi: 10.1097/HS9.0000000000000617. eCollection 2021 Aug. Hemasphere. 2021. PMID: 34350385 Free PMC article.
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K.
Mian AA, Haberbosch I, Khamaisie H, Agbarya A, Pietsch L, Eshel E, Najib D, Chiriches C, Ottmann OG, Hantschel O, Biondi RM, Ruthardt M, Mahajna J. Mian AA, et al. Among authors: ottmann og. Ann Hematol. 2021 Aug;100(8):2023-2029. doi: 10.1007/s00277-020-04357-z. Epub 2021 Jun 10. Ann Hematol. 2021. PMID: 34110462 Free PMC article.
Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study.
Ottmann OG, Stegelmann F, Breccia M, Steegmann JL, Olavarria E, Aimone P, Lipton JH. Ottmann OG, et al. Leuk Lymphoma. 2021 Mar;62(3):739-742. doi: 10.1080/10428194.2020.1839649. Epub 2020 Nov 6. Leuk Lymphoma. 2021. PMID: 33153366 Clinical Trial. No abstract available.
A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
Lang F, Wunderle L, Badura S, Schleyer E, Brüggemann M, Serve H, Schnittger S, Gökbuget N, Pfeifer H, Wagner S, Ashelford K, Bug G, Ottmann OG. Lang F, et al. Among authors: ottmann og. BMC Pharmacol Toxicol. 2020 Sep 29;21(1):70. doi: 10.1186/s40360-020-00446-x. BMC Pharmacol Toxicol. 2020. PMID: 32993794 Free PMC article. Clinical Trial.
250 results